Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

ng.  

"These very encouraging results to date support further evaluation of CCX140 in advanced clinical trials for the treatment of patients with type 2 diabetes," said Thomas J. Schall, President and Chief Executive Officer of ChemoCentryx.  "In addition to a high degree of target specificity and metabolic benefits, CCX140 is clearly differentiated from other marketed products with its added potential to treat the underlying mechanisms of type 2 diabetes and associated complications such as nephropathy and retinopathy.   The results of these trials continue to lead us to believe that CCX140 will be a meaningful and novel treatment option for patients who suffer from type 2 diabetes."

About Type 2 Diabetes and CCR2

Type 2 diabetes is a common metabolic disorder of high blood glucose associated with insulin resistance. It is differentiated from type 1 diabetes in which the primary defect is the inability of the pancreas to produce insulin. Patients with type 2 diabetes often require medication to maintain glucose homeostasis. The incidence of type 2 diabetes has reached epidemic proportions, associated in part with the rise in the incidence of weight gain and sedentary lifestyle. Despite available therapies, such as metformin, sulfonylureas, thiazolidinediones, incretin mimetics and other therapies, an unmet medical need for safe and convenient treatments persists.

For decades, the presence of systemic markers of inflammation has been known to increase with obesity. The adipose tissue has been shown to express multiple inflammatory cytokines, including TNF-a, IL-6, and MCP-1, the expression levels of which correlate with the degree of adiposity. Several of these mediators, including MCP-1 (also called chemokine ligand 2 (CCL2)), the main ligand for CCR2, have been shown to impair insulin-stimulated glucose uptake in adipose tissue, skeletal muscle and liver, providing a link between inflamed adipose tissue and insu
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... WASHINGTON , March 1, 2015  USPlabs ... of the following and states that media reports ... false: On Saturday, February 28, 2015, ... issued a Public Notification on the contamination of ... Super Thermogenic (referred to below as "OEP") with ...
(Date:2/27/2015)... Va. , Feb. 27, 2015 ... confident or very confident substituting an interchangeable biosimilar ... products share the same nonproprietary name, according to ... Care Pharmacy,s (AMCP,s) Journal of Managed Care ... only about 25 percent of pharmacists would feel ...
(Date:2/27/2015)... 27, 2015 Pharmaceutical and biotech marketers are ... for the same indication. This can be a complex ... prevent one of their brands from gaining market share ... recent research by benchmarking firm, Best Practices, LLC, 75% ... rather than together as part of a franchise. Marketers ...
Breaking Medicine Technology:OEP Product Is Counterfeit 2Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2
... 15, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... biotechnology company focused on researching, developing, manufacturing and marketing ... the second quarter and first half ended June 30, ... Total net revenues increased by 29.0% ...
... PharMEDium Services, LLC, market leader for customized ... therapies, launched its new website, www.pharmedium.com , ... safety and ready-to-use pharmacy compounding services.  Hospital customers ... range of services designed to reduce waste, improve ...
Cached Medicine Technology:3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 23SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 33SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 43SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 63SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 73SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 83SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 93SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 103SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 113SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 123SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 133SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 143SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 153SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 163SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 173SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 183SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 19PharMEDium Unveils Drug Shortage and Usage Updates on New Website with Focus on Patient Safety 2
(Date:3/1/2015)... (PRWEB) March 01, 2015 The number ... substantially over the past few weeks in two New ... actively filing claims, the Firm announces. , A ... cases in the Bergen County proceeding established for products ... with a few weeks earlier, when 90 fewer cases ...
(Date:3/1/2015)... Indianapolis, Indiana (PRWEB) March 01, 2015 ... Indiana statewide Network Service Provider, announces NewWays Networking, ... provider. “By working with IFN, NewWays is ... to meet client’s demand for Internet bandwidth in ... Owner/Manager. , According to Cory Childs IFN ...
(Date:3/1/2015)... 2015 ERISAPros is pleased ... Roddy to the professional staff of its Compliance Department. ... The Ohio State University-Mortiz College of Law. Prior to ... working with several Fortune 500 companies as well as ... corporate benefits. Her experiences range from benefit plan design, ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 “ The Barrel ... monthly Tech Report, which takes a look at the latest ... Tropeano, the host of NewsWatch and a technology expert, conducted ... spiral adds flavor to drinks. , According to Home Distillation ... the best spirits. Well, there’s a pretty cool product that’ll ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2
... BUFFALO, N.Y. -- Researchers at the University at Buffalo ... is expected to have major implications for research and ... diseases. A paper appearing online in Nanomedicine: ... specific delivery of a chemotherapeutic drug to specific cells ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... the pandemic H1N1 flu last year in California, more ... died, California Department of Public Health researchers report. ... appeared to occur at similar rates as with seasonal ...
... , MONDAY, Nov. 1 (HealthDay News) -- The ... monounsaturated fat (MUFA), which are commonly found in nuts, seeds, ... sunflower oil, new research suggests. In the study, researchers ... to moderate elevated cholesterol levels to either a high-MUFA diet ...
... inhibited growth of ovarian cancer in both human cell lines ... being used to fight malignancies, according to a study by ... follows previous discovery by the same group showing that a ... as a biomarker to diagnose early stage ovarian cancer, when ...
... Mass. -- The plenary presentations at Neuroprosthetics 2010, an ... artificial limbs, will be available via a live webcast ... (Eastern Time) on Nov. 3, 2010. No registration is ... webcast and the full program for the symposium are ...
... slipping while walking off a curb, may seem relatively harmless, ... elderly individuals, according to a new study published in The ... As the population continues to age, it is important for ... deal with this issue, which could significantly impact the overall ...
Cached Medicine News:Health News:Cancer drug linked to quantum dots increases drug uptake, reduces inflammation 2Health News: Pandemic H1N1 Flu Hit Kids Hard in 2009 2Health News: Pandemic H1N1 Flu Hit Kids Hard in 2009 3Health News:Adding Monounsaturated Fats to Diet May Boost Heart Health 2Health News:Peptide being tested to treat atherosclerosis inhibits ovarian cancer growth 2Health News:Peptide being tested to treat atherosclerosis inhibits ovarian cancer growth 3Health News:Neuroprosthetics symposium to be webcast live from Worcester Polytechnic Institute Nov. 3 2Health News:For elderly, even short falls can be deadly 2Health News:For elderly, even short falls can be deadly 3
... BrainSUITE iMRI is a neurosurgical ... surgical and diagnostic tools, including iMRI, ... With BrainSUITE iMRI, neurosurgical treatments are ... Pre-tested and designed for MR compatibility ...
... magnetic stimulator to offer the practical advantages ... designed to provide the simplest operation possible ... the same time, it may also help ... operations without moving away from your patient). ...
... System is a single-use, ... thrombus removal in native ... vein grafts. Self-contained ... and,continuous evacuation. Available ...
... MAX Cooling Power, Deeper Lesions ,Designed ... atrial flutter, Freezor MAX is a powerful ... an 8mm ablation tip was designed to ... to the same cryoconsole as the other ...
Medicine Products: